Riesmeijer, Sophie A. http://orcid.org/0000-0001-9196-7361
Kamali, Zoha http://orcid.org/0000-0001-6492-5887
Ng, Michael http://orcid.org/0000-0003-3463-5568
Drichel, Dmitriy
Piersma, Bram
Becker, Kerstin
Layton, Thomas B.
Nanchahal, Jagdeep http://orcid.org/0000-0002-9579-9411
Nothnagel, Michael http://orcid.org/0000-0001-8305-7114
Vaez, Ahmad http://orcid.org/0000-0001-9048-3795
Hennies, Hans Christian http://orcid.org/0000-0001-7210-2389
Werker, Paul M. N.
Furniss, Dominic http://orcid.org/0000-0003-2780-7173
Nolte, Ilja M. http://orcid.org/0000-0001-5047-4077
Article History
Received: 7 June 2022
Accepted: 13 December 2023
First Online: 3 January 2024
Competing interests
: The authors have the following to disclose: P.W. was science and engineering research board (SERB) member for an industry sponsored study on collagenase of Fidia Ltd, Milan, Italy. J.N. consults for and holds equity in 180 Life Sciences, which has exclusively licensed IP from the University of Oxford on the use of anti-TNF for early-stage Dupuytren’s disease. All other authors declare no competing interests.